 |
Hikma and Celltrion sign exclusive licensing agreementHikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, has signed an exclusive licensing agreement with Celltrion and Celltrion Healthcare (Celltrion) for Yuflyma (CT-P17). CT-P17 is the first adalimumab biosimilar with a h More… |
 |
Hikma delivers 'strong financial and operational performance'Hikma Pharmaceuticals, the multinational pharmaceutical company, has reported its interim results for the six months ended June 30, 2021. During the first half of 2021, core group revenue grew seven per c More… |
|
Hikma delivers 'strong financial and operational performance'Hikma Pharmaceuticals, the multinational pharmaceutical company, has reported its interim results for the six months ended June 30, 2021. During the first half of 2021, core group revenue grew seven per c More… |
 |
Hikma 2018 revenues up 7pc to top $2bnHikma Pharmaceuticals, a multinational generic pharmaceutical company, has posted revenues of $2.07 billion in 2018, as against $1.936 billion in the previous year, marking an increase of 7 per cent. The results reflect good deman More… |
 |
Hikma participates in 2019 World Economic ForumHikma Pharmaceuticals, a multinational generic pharmaceutical company, has participated in the 2019 World Economic Forum (WEF) Annual Meeting held in Davos, Switzerland, for the eleventh consecutive year. Under the theme of &lsquo More… |
 |
Hikma, Celltrion reach Truxima licensing agreementHikma Pharmaceuticals has reached a licensing agreement with South Korea-based Celltrion and Celltrion Healthcare for the first biosimilar monoclonal Antibody (mAb) in oncology to be granted European marketing authorisation, Truxima (rituximab). More… |
 |
Hikma to join FTSE 100 index on London SEHikma Pharmaceuticals, a leading multinational pharmaceutical group, will join the FTSE 100 Index, comprising the 100 most highly capitalised blue chip companies listed on the London Stock Exchange, as of March 24. Mazen Darwazah, More… |
|
Hikma to join FTSE 100 index on London SEHikma Pharmaceuticals, a leading multinational pharmaceutical group, will join the FTSE 100 Index, comprising the 100 most highly capitalised blue chip companies listed on the London Stock Exchange, as of March 24. Mazen Darwazah, More… |
 |
Hikma opens oncology plant in JordanHikma Pharmaceuticals, a multinational group, recently opened its chemical plant for oncology active pharmaceutical ingredients (API) specialised in producing effective raw materials for cancer medications. The plant was inaugurat More… |
 |
Hikma H1 revenue up 16pc to $738mHikma Pharmaceuticals, a major multinational pharmaceutical group with operations across Mena, Europe and the US, reported a 16 per cent increase in Group revenue to $738 million during first six months of the year. The increase i More… |
